StreetInsider.com News Articles

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Tue, 14 Jul 2026 16:05:00 -0400

VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Tue, 14 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the company’s investor

Form 4 Absci Corp For: Jun 30 Filed by: Szela Mary T

Mon, 06 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26735477.html

Form 4 Absci Corp For: Jun 30 Filed by: Szela Mary T

Mon, 06 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26735477.html

Absci Corp. (ABSI) PT Raised to $17 at Truist Securities

Thu, 02 Jul 2026 07:07:36 -0400

Truist Securities analyst Robyn Karnauskas raised the price target on Absci Corp. (NASDAQ: ABSI) to $17.00 (from $11.00) while maintaining a Buy rating.

Form 4 Absci Corp For: Jun 24 Filed by: McClain Sean

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699156.html

Form 4 Absci Corp For: Jun 24 Filed by: McClain Sean

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699156.html

Absci Corp. (ABSI) PT Raised to $10 at Morgan Stanley

Thu, 25 Jun 2026 08:53:17 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Absci Corp. (NASDAQ: ABSI) to $10.00 (from $4.10) while maintaining a Equalweight rating.

Absci Corp. (ABSI) PT Raised to $16 at H.C. Wainwright

Thu, 25 Jun 2026 06:48:43 -0400

(Updated - June 25, 2026 6:48 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Absci Corp. (NASDAQ: ABSI) to $16.00 (from $8.00) while maintaining a Buy rating.

The analyst commented: "Positive SAD HV data with a $100M strategic raise. On June 24, 2026, Absci reported interim results from the blinded single ascending dose (SAD) portion of the Phase 1/2a HEADLINE study evaluating ABS-201, a non-hormonal anti-prolactin receptor (PRLR) antibody, in 32 healthy volunteers, some of whom had androgenetic alopecia (AGA) (data cutoff: June 8, 2026). Participants received intravenous (IV) ABS-201 (150mg, 450mg, 900mg, or 1800mg) or placebo, and

Absci Corp. (ABSI) PT Raised to $16 at H.C. Wainwright

Thu, 25 Jun 2026 06:48:43 -0400

(Updated - June 25, 2026 6:48 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Absci Corp. (NASDAQ: ABSI) to $16.00 (from $8.00) while maintaining a Buy rating.

Form 8-K Absci Corp For: Jun 24

Wed, 24 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260624/26685981.html

Form 8-K Absci Corp For: Jun 24

Wed, 24 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260624/26685981.html

Form 424B5 Absci Corp

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685947.html

Form 424B5 Absci Corp

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685947.html

Absci Corp. (ABSI) PT Raised to $13 at Jones Trading

Wed, 24 Jun 2026 14:18:16 -0400

Jones Trading analyst Debanjana Chatterjee raised the price target on Absci Corp. (NASDAQ: ABSI) to $13.00 (from $11.00) while maintaining a Buy rating.

Absci prices $100M stock offering with Eli Lilly among investors

Wed, 24 Jun 2026 06:35:43 -0400

Absci Corporation (Nasdaq: ABSI) priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share, expecting to raise approximately $100 million in gross proceeds before underwriting discounts, commissions, and offering expenses, according to a press release.

The offering includes participation from Eli Lilly & Company alongside Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and an unnamed large investment management firm. All shares are being sold by Absci, and the offering was expected to close on or about June 25, 2026, subject to customary closing conditions.

Absci said it intends to use the net proceeds to advance ABS-201, its

Absci prices $100M stock offering with Eli Lilly among investors

Wed, 24 Jun 2026 06:35:43 -0400

Absci said it intends to use the net proceeds to advance ABS-201, its

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Wed, 24 Jun 2026 06:35:00 -0400

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis

VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions.

The gross

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Wed, 24 Jun 2026 06:35:00 -0400

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis

The gross

Form 8-K Absci Corp For: Jun 24

Wed, 24 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260624/26681907.html

Form 8-K Absci Corp For: Jun 24

Wed, 24 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260624/26681907.html

Absci reports Phase 1 safety data for hair loss antibody ABS-201

Wed, 24 Jun 2026 06:30:16 -0400

Absci Corporation (Nasdaq: ABSI) reported interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201, an investigational antibody targeting the prolactin receptor, according to a company press release.

The trial enrolled 32 healthy adult participants across four single ascending dose cohorts receiving 150 mg, 450 mg, 900 mg, and 1,800 mg of ABS-201 administered intravenously. Data were cut off as of June 8, 2026.

No serious adverse events were reported across any cohort. Treatment-emergent adverse events were reported in 16 of 32 participants, with the majority mild in severity. One moderate adverse event — a headache in the 900 mg cohort

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Wed, 24 Jun 2026 06:30:00 -0400

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts

Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period

First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated

Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027

VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Wed, 24 Jun 2026 06:30:00 -0400

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts

Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period

First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated

Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027

VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Tue, 16 Jun 2026 08:45:00 -0400

Issued on behalf of MindWalk Holdings Corp.

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.

NEW YORK, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models,